




The development of IARC's Medium-Term Strategy 2021–2025

Dr Elisabete Weiderpass, Director
International Agency for Research on Cancer
Lyon, France

MEDIUM-TERM STRATEGY 2021–2025

Preparatory work





**Recommendations
informed MTS discussions**



Inclusive, transparent and focused strategic prioritization process



Strengthened collaboration with WHO (Science Division)



Future-focused balance between in-house and external laboratory capacities



Additional laboratory, bioinformatics, and other expertise through collaboration, Visiting Scientists, and secondments from PS

MEDIUM-TERM STRATEGY 2021–2025

Preparatory work: Stakeholders' consultation – Conclusions



Conclusions informed MTS discussions



On strategic priorities

- Continue focus on **IARC's fundamental priorities**
- Strengthen engagement in **emerging priorities**, emphasize **implementation research**



On positioning IARC:

- Communicate **IARC's mandate and role** more effectively
- Highlight IARC's **public health impact**
- Enhance **IARC's visibility in non-scientific** cancer community.



On strategic partnerships:


- Explore **strategic engagement** with non-traditional partners
- Seek **Cooperation Agreements and specific collaboration projects**.

MEDIUM-TERM STRATEGY 2021–2025

Preparatory work: A new Mission for IARC



Cancer Research that Matters

- 
- Research that ultimately makes a difference in people's lives. Research that positively affects life expectancy.
 - *How?*
Intentionally pursue cancer research and science that is expected to positively and notably affect people's health.
 - Strengthen engagement, resources and collaboration in priority areas when conducting scientific and research work.

MEDIUM-TERM STRATEGY 2021–2025

Preparatory work : IARC's Comparative Advantages

1 Global scientific convening power and large collaborative research networks

2 Research & capacity building in LMICs

3 Open and neutral research platform

1

2

3



4

5

4 Independent and impartial authority on carcinogenicity & cancer burden

5 UN family member/ WHO affiliation



N O U V E A U C E N T R E



CANCER PREVENTION

Who gets cancer?

Why do we get cancer?

Which measures work to prevent it?

Mobilizing the knowledge gained & Building global capacity





- Strategic guidance and advice on IARC's new MTS 2021–2025
- Four remote Working Group meetings and three reviews of the draft MTS
 - Including two comprehensive reviews through all relevant WHO Divisions and Departments
- **Draft MTS 2021–2025 represents the result of productive discussions, exchanges of views and a forward-looking collaboration between IARC's Governing Bodies and the Secretariat.**

4

MEDIUM-TERM STRATEGY 2021–2025

Next steps



May 2020

Engage with Joint
GC/SC MTS WG



Dec. 2020

Draft MTS 2021–2025
submitted to SC
meeting



June – October 2020
draft MTS 2021–2025
formulated jointly by
GC/SC MTS WG and
Secretariat



Feb. 2021

IARC Scientific Council
discusses draft MTS 2021–2025



May 2021

IARC Governing Council
reviews final draft
MTS 2021–2025



4 MEDIUM-TERM STRATEGY 2021–2025

Look into the future

Implementing the MTS 2021–2025 will facilitate the transition towards a stronger IARC:

- Global hub for open science for cancer prevention
- Leader in prevention research
- Recognized for public health impact
- Global capacity builder for cancer science and research

